Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Pharmos’ Synthetic Cannabinoid Disappoints In Phase IIa

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company will study oral cannabinor for neuropathic pain, adjust intravenous dosing for nociceptive pain.

You may also be interested in...



‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly

Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.

‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly

Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.

Canadian Firms Partner On Cannabinoid-Based Therapies For Mood Disorders

Anxiety and depression are on the list of disorders targeted by Cannasat/IntelGenx collaboration to develop cannabinoid-based CAT 320.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

See All
UsernamePublicRestriction

Register

PS065039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By